International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 416-419 www.ijprajournal.com ISSN: 2456-4494

Pharmacological Targeting of the Gut–Brain Axis: New Horizons in Neurology and Psychiatry

[1]Nisha Sonker, [2]Dr Shailendra Kawre, [3]Rohit Kori, [4]Dr Siddharth Verma
1.Associate Professor, SirAtma Ram Institute of Pharmacy & Technology, Jabalpur, M.P.
2.Professor, DrBhagat Singh Rai College of Pharmacy, Seoni, M.P.
3.Assistant Professor, DBM College of Pharmacy, Champa, C.G.
4.Professor, CSSCP, Prayagraj U.P.

Date of Submission: 10-09-2025 Date of Acceptance: 20-09-2025

ABSTRACT
The gut–brain axis (GBA) is an intricate bidirectional communication system linking the gastrointestinal tract and the central nervous system. This crosstalk is mediated through neural, immune, endocrine, and metabolic pathways, with the gut microbiota emerging as a pivotal regulator. Accumulating evidence highlights the role of gut microbiota in mood regulation, stress response, cognitive function, and neurodevelopmental processes. Dysbiosis, or imbalance of gut microbes, has been implicated in major depressive disorder, anxiety disorders, Parkinson's disease, Alzheimer's disease, and autism spectrum disorders. Consequently, pharmacological targeting of the GBA has become an exciting frontier encompassing probiotics, prebiotics, postbiotics, fecal microbiota transplantation (FMT), antibiotics, dietary interventions, and psychobiotic drugs. This review synthesizes mechanistic understanding, preclinical and clinical evidence, therapeutic strategies, limitations, and future directions, emphasizing precision microbiome medicine and translational challenges.

I. INTRODUCTION

The concept of bidirectional gut–brain communication has rapidly evolved from speculative observations to a data-rich scientific field. The GBA integrates signals from the enteric nervous system (ENS), the central nervous system (CNS), endocrine pathways including the hypothalamic–pituitary–adrenal (HPA) axis, immune mediators, and microbial metabolites. The gut microbiota—comprising bacteria, viruses, fungi, and archaea—plays active roles in metabolite production (e.g., short-chain fatty acids), neurotransmitter biosynthesis (serotonin, γ-aminobutyric acid [GABA], dopamine), and modulation of immune tone. Advances in high-throughput sequencing, metabolomics, and neuroimaging have enabled mechanistic linking of microbiome features with behavioral and cognitive phenotypes.

MECHANISMS OF THE GUT–BRAIN AXIS

Neural Pathways: The vagus nerve represents a primary neural highway that transmits microbial and gut-derived signals to brainstem nuclei, modulating mood and autonomic responses. Enterochromaffin cells in the gut epithelium sense luminal factors and relay information via vagal afferents and ENS circuits. The ENS itself contains millions of neurons and can operate semi-autonomously to coordinate motility and secretion.

Endocrine Pathways: Activation of the HPA axis under stress results in CRH, ACTH, and cortisol release, which have downstream effects on gut permeability, microbial composition, and inflammatory responses. Gut peptides such as GLP-1, peptide YY, and ghrelin act as metabolic and neuromodulatory messengers influencing appetite and cognitive states.

Immune Pathways: Gut microbes regulate mucosal immunity and systemic cytokine profiles. Dysbiosis can provoke chronic low-grade inflammation with elevated cytokines (e.g., IL-6, TNF-α), capable of crossing or signaling across the blood–brain barrier (BBB) and altering microglial activation.

Metabolic Pathways: Microbial fermentation of dietary fibers generates short-chain fatty acids (SCFAs)—notably acetate, propionate, and butyrate—which support epithelial barrier integrity, modulate T-regulatory cell populations, and influence brain function via epigenetic and metabolic signaling. Microbial metabolites of tryptophan affect serotonergic pathways and kynurenine metabolism, implicated in mood disorders.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 416-419 www.ijprajournal.com ISSN: 2456-4494

GUT MICROBIOTA AND NEUROLOGICAL & PSYCHIATRIC DISORDERS

Depression and Anxiety: An expanding literature links gut dysbiosis with altered tryptophan metabolism, increased inflammatory markers, and behavioral changes. Rodent models demonstrate that germ-free mice exhibit exaggerated stress responses and altered social behavior that normalize after microbiota restoration. Clinical randomized controlled trials (RCTs) and meta-analyses indicate modest benefits of certain probiotic strains (e.g., Lactobacillus helveticus R0052, Bifidobacterium longum R0175) on depressive and anxiety symptoms, although heterogeneity in study design remains a limitation.

Parkinson's Disease: Prodromal gastrointestinal dysfunction, especially constipation, often precedes motor manifestations by years. Experimental studies suggest that α-synuclein pathology may originate in the gut and propagate to the brain via the vagus nerve. Altered gut bacterial taxa—such as reduced Prevotella and increased Enterobacteriaceae—correlate with motor severity and may modulate neuroinflammation.

Alzheimer's Disease: Dysbiosis is associated with systemic inflammation, altered bile acid metabolism, and amyloidogenic processes. SCFAs and other microbial metabolites may exert neuroprotective or deleterious effects depending on context. Early-phase trials testing probiotics and dietary interventions report heterogeneous cognitive outcomes, with some suggesting modest improvement in inflammatory biomarkers and cognition.

Autism Spectrum Disorder: Children with ASD frequently present with gastrointestinal symptoms and microbial signatures distinct from neurotypical peers—characterized by altered Firmicutes/Bacteroidetes ratios and elevated Clostridium species in some cohorts. Interventional studies using probiotics, prebiotics, and FMT report improvements in GI symptoms and, in some cases, behavioral measures, but long-term safety and reproducibility require rigorous assessment.

PHARMACOLOGICAL INTERVENTIONS TARGETING THE GBA

Probiotics (Psychobiotics): Defined as live microorganisms conferring health benefits, psychobiotics are selected for neuroactive properties. Mechanisms include modulation of inflammatory pathways, production of neurotransmitter precursors, strengthening of gut barrier function, and interactions with the ENS and vagal pathways. Commonly researched strains include Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium longum, and Bifidobacterium breve. Clinical effects vary by strain, dose, and host factors. Prebiotics: Non-digestible oligosaccharides such asfructooligosaccharides (FOS) and galactooligosaccharides (GOS) promote growth of beneficial microbes, elevate SCFA production, and have been linked to reduced cortisol and improved emotional processing in small human trials.

Postbiotics: These are preparations of inactivated microbial cells or metabolic byproducts (e.g., butyrate) that can retain immunomodulatory and neuroactive functions while offering enhanced safety profiles relative to live microbes. Preclinical data indicate neuroprotective and anti-inflammatory effects of selected postbiotics.

Fecal Microbiota Transplantation (FMT): FMT transfers a complex microbial community from a healthy donor to a recipient to reset microbiome composition. While highly effective for recurrent Clostridioides difficile infection, FMT for neuropsychiatric disorders is investigational. Pilot studies report symptomatic improvements in ASD and depression, but standardization of donor selection, preparation, and delivery method is required to mitigate risks.

Antibiotics and Microbiome Editing: Short courses of broad-spectrum antibiotics can transiently shift microbiome composition; narrow-spectrum or targeted antimicrobials and bacteriophage therapies represent avenues for selective microbiome editing. Risks include resistance development and collateral damage to beneficial taxa.

Dietary Interventions and Nutraceuticals: Mediterranean-style diets, high in fiber and polyphenols, consistently improve microbial diversity and reduce systemic inflammation. Specific nutraceuticals—omega-3 fatty acids, curcumin, resveratrol—exert microbiota-mediated effects and have shown potential in mood and cognitive disorders.

CURRENT & EMERGING THERAPIES

Antidepressant–Microbiome Interactions: Many psychotropic drugs alter microbial communities (e.g., SSRIs, tricyclic antidepressants), which may contribute to therapeutic and adverse effects. Understanding bidirectional drug–microbiome interactions can inform combined therapeutic strategies.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 416-419 www.ijprajournal.com ISSN: 2456-4494

GLP-1 Receptor Agonists and Metabolic–Neuroprotective Links: Agents such as liraglutide and semaglutide show neuroprotective properties in preclinical models and are under evaluation for neurodegenerative conditions. Their modulation of gut hormones and metabolic state places them at an intersection of metabolic and neuropharmacology.

Engineered Probiotics and Live Biotherapeutic Products (LBPs): Synthetic biology enables engineering of microbes to produce therapeutic peptides, neurotransmitters, or immunomodulatory molecules in situ. LBPs are progressing through regulatory frameworks and early-phase clinical trials.

Nanotechnology-Enhanced Delivery: Encapsulation techniques and microencapsulation improve viability and targeted release of probiotics, while nanoparticle-based carriers enable controlled delivery of postbiotics and small molecules across biological barriers.

CHALLENGES & LIMITATIONS

Inter-individual Variability: Microbiome profiles are shaped by diet, geography, age, genetics, medication exposure, and early-life events, complicating extrapolation of clinical trial results.

Standardization & Regulatory Issues: Lack of consensus on probiotic strain selection, dosing, FMT donor screening, and quality control poses regulatory hurdles. Live biotherapeutic products require stringent safety and manufacturing oversight.

Safety Concerns: While generally safe in healthy populations, probiotics and FMT carry risks—bacteremia, transfer of pathogenic organisms, and metabolic perturbations—especially in immunocompromised individuals.

Evidence Quality: Many studies are small, heterogeneous, and of short duration. There is a need for large RCTs with standardized endpoints, longitudinal follow-up, and mechanistic biomarkers.

Complex Causality: Disentangling cause from effect remains a challenge—many microbiome alterations may be consequences rather than drivers of neuropsychiatric disease.

FUTURE PROSPECTS

Precision Microbiome Medicine: Integration of multi-omics (metagenomics, metabolomics, transcriptomics) with clinical phenotyping will enable personalized interventions such as tailored psychobiotic formulations or dietary prescriptions.

Artificial Intelligence & Systems Biology: Machine learning approaches can identify predictive microbiome signatures, model microbiome–drug interactions, and optimize donor–recipient matching in FMT.

Next-Generation Therapeutics: Designer probiotics, bacteriophage therapy, microbiome-derived small molecules, and targeted microbiome editing represent a pipeline of innovative therapies. Combination strategies pairing psychobiotics with conventional psychotropics may enhance efficacy and reduce side effects.

Biomarker Development: Reliable biomarkers (microbial taxa, metabolites, immune markers) are critical for patient stratification, monitoring therapeutic response, and predicting adverse effects.

II. CONCLUSION

Pharmacological targeting of the gut–brain axis offers a transformative frontier for neurology and psychiatry, shifting paradigms from solely CNS-centric approaches to integrated microbiome-aware therapeutics. Although early clinical data are promising, rigorous large-scale trials, robust safety frameworks, and precision strategies are required to translate experimental insights into routine clinical practice. The convergence of microbiology, neuroscience, pharmacology, and computational biology holds promise to unlock novel interventions that ameliorate psychiatric and neurodegenerative disorders by harnessing the therapeutic potential of the gut microbiome.

REFERENCES

[1]. Cryan JF, O'Riordan KJ, Cowan CSM, et al. The microbiota–gut–brain axis. Physiol Rev. 2019;99(4):1877-2013.
[2]. Dinan TG, Stanton C, Cryan JF. Psychobiotics: a novel class of psychotropic. Biol Psychiatry. 2013;74(10):720-726.
[3]. Sampson TR, Mazmanian SK. Control of brain development, function, and behavior by the microbiome. Cell Host Microbe. 2015;17(5):565-576.
[4]. Quigley EM. Microbiota–gut–brain axis and neurodegenerative diseases. Curr Neurol Neurosci Rep. 2017;17(12):94.
[5]. Wang HX, Wang YP. Gut microbiota–brain axis in neuropsychiatric disorders.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 416-419 www.ijprajournal.com ISSN: 2456-4494

World J Gastroenterol. 2016;22(12):5536-5541.

[6]. Mulle JG, Sharp WG, Cubells JF. The gut microbiome: a new frontier in autism research. Curr Psychiatry Rep. 2013;15(2):337.

[7]. Hsiao EY, McBride SW, Hsien S, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155(7):1451-1463.

[8]. Kelly JR, Borre Y, O' Brien C, et al. Transferring the blues: depression-associated gut microbiota induces neurobehavioural changes in the rat. J Psychiatr Res. 2016;82:109-118.

[9]. Keshavarzian A, Green SJ, Engen PA, et al. Colonic bacterial composition in Parkinson's disease. Mov Disord. 2015;30(10):1351-1360.

[10]. Vogt NM, Kerby RL, Dill-Mcfarland KA, et al. Gut microbiome alterations in Alzheimer's disease. Sci Rep. 2017;7:13537.

[11]. Fragkos KC, Sergentis T, Stamatelatos G, et al. Probiotics for the treatment of depression and anxiety: A systematic review. Nutrients. 2020;12(8):2340.

[12]. Morshedi M, Ghaedi E, Salehi A. The influence of probiotics on mental health: an updated review of randomized clinical trials. Curr Psychiatry Rep. 2021;23(5):1-12.

[13]. Kelly JR, Allen AP, Temko A, et al. Lost in translation? Moving from preclinical microbiome studies to human trials. Gut Microbes. 2017;8(5):450-450.

[14]. D'Angelo M, Martucci M, Troise F, et al. Fecal microbiota transplantation (FMT) in neuropsychiatric disorders: A systematic review. Front Psychiatry. 2022;13:876.

[15]. Liang S, Wu X, Jin F. Gut-brain psychology: rethinking psychology from the microbiota–gut–brain axis. Front Integr Neurosci. 2018;12:33.

[16]. Kelly JR, Borre Y, O' Brien C, et al. From gut to brain: the microbiome and mental health. Eur Neuropsychopharmacol. 2016;26(10):1705-1721.

[17]. Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018;1693(Pt B):128-133.

[18]. Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev. 2010;31(6):958-987.

[19]. Hsaio YT, et al. Microbial metabolites and neurodegeneration: the role of SCFAs. Trends Neurosci. 2020;43(8):401-414.

[20]. Sherwin E, Sandhu KV, Dinan TG, Cryan JF. May the force be with you: the light and dark sides of the microbiome–gut–brain axis in neuropsychiatry. CNS Drugs. 2016;30(11):1019-1041.

[21]. Clarke G, Stilling RM, Kennedy PJ, et al. Minireview: gut microbiota: the neglected endocrine organ. Mol Endocrinol. 2014;28(8):1221-1238.

[22]. Sudo N. Microbiome, HPA axis and production of endocrine neurotransmitters in the gut. Adv Exp Med Biol. 2014;817:177-194.

[23]. Dinan TG, Cryan JF. Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration. J Physiol. 2017;595(2):489-503.

[24]. Zhai Q, Feng S, Arjan N, Chen W. A next generation of probiotics: Akkermansia muciniphila. Trends Food Sci Technol. 2019;84:123-135.

[25]. O'Mahony SM, Clarke G, Borre YE, et al. Serotonin, tryptophan metabolism and the brain–gut–microbiome axis. Behav Brain Res. 2015;277:32-48.

[26]. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut–brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203-209.

[27]. Dinan TG, Cryan JF. The microbiome–gut–brain axis in health and disease. Gastroenterol Clin North Am. 2017;46(1):77-89.

[28]. Hsiao EY. Microbiota–brain interactions in autism spectrum disorder. Biol Psychiatry. 2014;75(5):399-400.

[29]. Barrett E, Ross RP, O'Toole PW, et al. γ-Aminobutyric acid production by culturable bacteria from the human intestine. J Appl Microbiol. 2012;113(2):411-417.

[30]. Sharon G, Sampson TR, Geschwind DH, Mazmanian SK. The central nervous system and the gut microbiome. Cell. 2016;167(4):915-932.